ulcerative colitis

News

MSD's tulisokibart has become the first anti-TL1A antibody to help patients with ulcerative colitis achieve clinical remission in a phase 3 trial.

News

Shares in Abivax have tumbled after it announced phase 3 data with ulcerative colitis drug obefazimod that included several cases of cancer.

News

MSD is paying $20m upfront to activate an alliance with Flagship's Quotient Therapeutics to find new targets in inflammatory bowel disease.

News

Earendil has raised an impressive $787m in financing for its AI-powered drug platform, attracting yet more buy-in from Sanofi.

R&D

Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.

News

Boehringer Ingelheim has sourced an IL-23p19xTL1A bispecific antibody for inflammatory bowel disease, from China's Simcere, for €42m upfront.